Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press63610.17650/1994-4098-2019-15-1-73-77GYNECOLOGY. CLINICAL CASEГИНЕКОЛОГИЯ. КЛИНИЧЕСКИЙ СЛУЧАЙSuccessful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case reportУспешный опыт лечения метастатического рака эндометрия с микросателлитной нестабильностью ингибитором PD-1: клинический случайhttps://orcid.org/0000-0001-7110-6505AndabekovT. T.АндабековТ. Т.
Russian Federation

Build. 1, 18, Turistskaya St., Saint Petersburg 197082

Тимур Турдеевич Андабеков

197082 Санкт-Петербург, ул. Туристская, 18, корп. 1

andabekovtt@mail.ruRodinaM. K.РодинаМ. К.
Russian Federation

Build. 1, 18, Turistskaya St., Saint Petersburg 197082

197082 Санкт-Петербург, ул. Туристская, 18, корп. 1

RaskinG. A.РаскинГ. А.
Russian Federation

Medical Faculty, Saint Petersburg State University

70 Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758, 

2–4 Ligovskiy prospekt, Saint Petersburg 191036, 

7–9 Universitetskaya naberezhnaya, Saint Petersburg 199034

Медицинский факультет ФГБОУ ВО «Санкт-Петербургский государственный университет»

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70, 

191036 Санкт-Петербург, Лиговский проспект, 2–4, 

199034 Санкт-Петербург, Университетская набережная, 7–9

ChamK. G.ЧамК. Г.
Russian Federation

70 Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70

RutkinI. O.РуткинИ. О.
Russian Federation

70 Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70

LLC “AV medical group”ООО «АВ медикал групп»A.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of RussiaФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» Минздрава РоссииSaint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of RussiaФГБУ «Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии» Минздрава РоссииSaint Petersburg State UniversityФГБОУ ВО «Санкт-Петербургский государственный университет»0107201915173770107201901072019https://ojrs.abvpress.ru/ojrs/article/view/636

High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events.

Показана высокая эффективность анти-PD-1 терапии при опухолях с нарушениями системы репарации ДНК. Обнаружено, что нарушения системы репарации ДНК определяются в 20–40 % всех случаев рака эндометрия и до 48 % – при его эндометриоидном подтипе. Мы представляем краткий обзор литературы по данному вопросу и случай длительного частичного ответа на иммунотерапию пембролизумабом у больной метастатическим эндометриоидным раком эндометрия с нарушениями системы репарации ДНК с прогрессированием заболевания на 2 линиях предшествующей химиотерапии. Частичный ответ достигнут после 6‑го курса, лечение прекращено после 8‑го курса. Пациентка находится под наблюдением без какого‑либо противоопухолевого лечения в течение 11 мес. Длительность частичного ответа составляет 13 мес, наблюдается дальнейшее уменьшение размеров опухоли. Лечение хорошо переносилось, нежелательные явления не наблюдались.

endometriоid adenocarcinomaendometrial carcinomadMMRMSI-himmunotherapyPD-1 inhibitorpembrolizumabэндометриоидная аденокарциномарак эндометрияdMMRMSI-hиммунотерапияингибитор PD-1пембролизумаб1. Murali R., Soslow R.A., Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15(7):e268–78. DOI: 10.1016/S1470-2045(13)70591-6.Murali R., Soslow R.A., Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15(7):e268–78. DOI: 10.1016/S1470-2045(13)70591-6.2. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5): E359–86. DOI: 10.1002/ijc.29210.Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5): E359–86. DOI: 10.1002/ijc.29210.3. Liu F.S. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007;46:26–32.Liu F.S. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007;46:26–32.4. Tinelli A., Mezzolla V., Leo G. et al. Microsatellite instability (MSI) as genomic markers in endometrial cancer: toward scientific evidences. Mini Rev Med Chem 2010;10:1356–65.Tinelli A., Mezzolla V., Leo G. et al. Microsatellite instability (MSI) as genomic markers in endometrial cancer: toward scientific evidences. Mini Rev Med Chem 2010;10:1356–65.5. Weigelt B., Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012;24:554–63. DOI: 10.1097/CCO.0b013e328354e585.Weigelt B., Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012;24:554–63. DOI: 10.1097/CCO.0b013e328354e585.6. Kunitomi H., Banno K., Yanokura M. et al. New use of microsatellite instability analysis in endometrial cancer. Oncol Lett 2017;14(3):3297–301. DOI: 10.3892/ol.2017.6640.Kunitomi H., Banno K., Yanokura M. et al. New use of microsatellite instability analysis in endometrial cancer. Oncol Lett 2017;14(3):3297–301. DOI: 10.3892/ol.2017.6640.7. Zaanan A., Meunier K., Sangar F. et al. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol (Dordr) 2011;34:155–76.Zaanan A., Meunier K., Sangar F. et al. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol (Dordr) 2011;34:155–76.8. Karamurzin Y., Zeng Z., Stadler Z.K. et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 2012;43:1677–87. DOI: 10.1016/j.humpath.2011.12.012.Karamurzin Y., Zeng Z., Stadler Z.K. et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 2012;43:1677–87. DOI: 10.1016/j.humpath.2011.12.012.9. Lawes D.A., SenGupta S., Boulos P.B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol 2003;29(3):201–12.Lawes D.A., SenGupta S., Boulos P.B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol 2003;29(3):201–12.10. Ligtenberg M.J., Kuiper R.P., Chan T.L. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 2009;41(1):112–7.Ligtenberg M.J., Kuiper R.P., Chan T.L. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 2009;41(1):112–7.11. Meyer L.A., Broaddus R.R., Lu K.H. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:14–22.Meyer L.A., Broaddus R.R., Lu K.H. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:14–22.12. Leenen C.H., van Lier M.G., van Doorn H.C. et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecol Oncol 2012;125:414–20. DOI: 10.1016/j.ygyno.2012.01.049.Leenen C.H., van Lier M.G., van Doorn H.C. et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecol Oncol 2012;125:414–20. DOI: 10.1016/j.ygyno.2012.01.049.13. Ta R.M., Hecht J.L., Lin D.I. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Gynecol Oncol 2018;151(3):401– 6. DOI: 10.1016/j.ygyno.2018.10.012.Ta R.M., Hecht J.L., Lin D.I. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Gynecol Oncol 2018;151(3):401– 6. DOI: 10.1016/j.ygyno.2018.10.012.14. Luchini C., Bibeau F., Ligtenberg M.J.L. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019;0:1–12. DOI: 10.1093/annonc/mdz116.Luchini C., Bibeau F., Ligtenberg M.J.L. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019;0:1–12. DOI: 10.1093/annonc/mdz116.15. Le D.T., Uram J.N., Wang H. et al. PD-1 Blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015;372(26):2509–20. DOI: 10.1056/NEJMoa1500596.Le D.T., Uram J.N., Wang H. et al. PD-1 Blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015;372(26):2509–20. DOI: 10.1056/NEJMoa1500596.